Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should be counselled about this risk Patient safety advice for those using GLP-1 receptor agonists includes: Report persistent nausea, vomiting, or abdominal pain to your GP promptly Stop treatment and seek urgent medical care if you develop severe, persistent abdominal pain that may suggest pancreatitis Maintain adequate hydration, especially during initial treatment and if experiencing vomiting or diarrhoea Monitor for signs of gallbladder problems (sustained upper right abdominal pain, fever, jaundice) Patients with diabetes should monitor blood glucose levels closely, particularly when starting treatment or adjusting doses Inform healthcare providers of all medications to assess interaction risks Report suspected side effects via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app Pregnant women or those planning pregnancy should not use GLP-1 receptor agonists
Statistical methods e trial and the methodologies for statistical comparison between test and reference formulations were designed taking into account the recommendations of the guidance on the investigation of bioequivalence (CPMP/QWP/EWP/1401/98 Rev
What are their key similarities and differences, and which one is the best option
It also advises against vitamin E for the prevention of cardiovascular disease and cancer, and warns of the potential risks of vitamin or mineral supplementation in general, recommending instead a healthy, balanced diet.78 The risks and benefits of systemic skin aging treatments must be carefully weighed up, as their purpose is to reverse or slow down a natural process rather than treat a particular disease
